151 related articles for article (PubMed ID: 27015662)
1. Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule.
Maaß C; Sachs JP; Hardiansyah D; Mottaghy FM; Kletting P; Glatting G
EJNMMI Res; 2016 Dec; 6(1):30. PubMed ID: 27015662
[TBL] [Abstract][Full Text] [Related]
2. Single-time-point estimation of absorbed doses in PRRT using a non-linear mixed-effects model.
Hardiansyah D; Riana A; Beer AJ; Glatting G
Z Med Phys; 2023 Feb; 33(1):70-81. PubMed ID: 35961809
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity Analysis of a Physiologically Based Pharmacokinetic Model Used for Treatment Planning in Peptide Receptor Radionuclide Therapy.
Hardiansyah D; Begum NJ; Kletting P; Mottaghy FM; Glatting G
Cancer Biother Radiopharm; 2016 Aug; 31(6):217-24. PubMed ID: 27403777
[TBL] [Abstract][Full Text] [Related]
4. Treatment planning in PRRT based on simulated PET data and a PBPK model. Determination of accuracy using a PET noise model.
Hardiansyah D; Guo W; Attarwala AA; Kletting P; Mottaghy FM; Glatting G
Nuklearmedizin; 2017 Feb; 56(1):23-30. PubMed ID: 27885372
[TBL] [Abstract][Full Text] [Related]
5. The role of patient-based treatment planning in peptide receptor radionuclide therapy.
Hardiansyah D; Maass C; Attarwala AA; Müller B; Kletting P; Mottaghy FM; Glatting G
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):871-880. PubMed ID: 26577941
[TBL] [Abstract][Full Text] [Related]
6. Prediction of time-integrated activity coefficients in PRRT using simulated dynamic PET and a pharmacokinetic model.
Hardiansyah D; Attarwala AA; Kletting P; Mottaghy FM; Glatting G
Phys Med; 2017 Oct; 42():298-304. PubMed ID: 28739143
[TBL] [Abstract][Full Text] [Related]
7. A simulation-based method to determine optimal sampling schedules for dosimetry in radioligand therapy.
Rinscheid A; Lee J; Kletting P; Beer AJ; Glatting G
Z Med Phys; 2019 Dec; 29(4):314-325. PubMed ID: 30611606
[TBL] [Abstract][Full Text] [Related]
8. Influence of sampling schedules on [
Rinscheid A; Kletting P; Eiber M; Beer AJ; Glatting G
EJNMMI Phys; 2020 Jun; 7(1):41. PubMed ID: 32556844
[TBL] [Abstract][Full Text] [Related]
9. Accuracy and uncertainty analysis of reduced time point imaging effect on time-integrated activity for
Peterson AB; Mirando DM; Dewaraja YK
EJNMMI Res; 2023 Jun; 13(1):57. PubMed ID: 37306783
[TBL] [Abstract][Full Text] [Related]
10. Accuracy and uncertainty analysis of reduced time point imaging effect on time-integrated activity for 177Lu-DOTATATE PRRT in clinical patients and realistic simulations.
Peterson AB; Mirando DM; Dewaraja YK
Res Sq; 2023 Apr; ():. PubMed ID: 37131738
[No Abstract] [Full Text] [Related]
11. Optimized Peptide Amount and Activity for ⁹⁰Y-Labeled DOTATATE Therapy.
Kletting P; Kull T; Maaß C; Malik N; Luster M; Beer AJ; Glatting G
J Nucl Med; 2016 Apr; 57(4):503-8. PubMed ID: 26678617
[TBL] [Abstract][Full Text] [Related]
12. Time-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: A simulation study on the effect of sampling schedule and noise.
Hardiansyah D; Guo W; Kletting P; Mottaghy FM; Glatting G
Med Phys; 2016 Sep; 43(9):5145. PubMed ID: 27587044
[TBL] [Abstract][Full Text] [Related]
13. Physiologically based pharmacokinetic modeling of (18)F-SiFAlin-Asp3-PEG1-TATE in AR42J tumor bearing mice.
Maaß C; Rivas JR; Attarwala AA; Hardiansyah D; Niedermoser S; Litau S; Wängler C; Wängler B; Glatting G
Nucl Med Biol; 2016 Apr; 43(4):243-6. PubMed ID: 27067044
[TBL] [Abstract][Full Text] [Related]
14. Comparison of commercial dosimetric software platforms in patients treated with
Mora-Ramirez E; Santoro L; Cassol E; Ocampo-Ramos JC; Clayton N; Kayal G; Chouaf S; Trauchessec D; Pouget JP; Kotzki PO; Deshayes E; Bardiès M
Med Phys; 2020 Sep; 47(9):4602-4615. PubMed ID: 32632928
[TBL] [Abstract][Full Text] [Related]
15. Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in
Rinscheid A; Kletting P; Eiber M; Beer AJ; Glatting G
Med Phys; 2019 Dec; 46(12):5861-5866. PubMed ID: 31587333
[TBL] [Abstract][Full Text] [Related]
16. Population-Based Modeling Improves Treatment Planning Before (90)Y-Labeled Anti-CD66 Antibody Radioimmunotherapy.
Maaß C; Kletting P; Bunjes D; Mahren B; Beer AJ; Glatting G
Cancer Biother Radiopharm; 2015 Sep; 30(7):285-90. PubMed ID: 26172337
[TBL] [Abstract][Full Text] [Related]
17. Accuracy and reproducibility of simplified QSPECT dosimetry for personalized
Del Prete M; Arsenault F; Saighi N; Zhao W; Buteau FA; Celler A; Beauregard JM
EJNMMI Phys; 2018 Oct; 5(1):25. PubMed ID: 30318563
[TBL] [Abstract][Full Text] [Related]
18. Patient-specific dosimetry of
Hou X; Birkenfeld B; Piwowarska-Bilska H; Celler A
EJNMMI Phys; 2017 Oct; 4(1):24. PubMed ID: 29030760
[TBL] [Abstract][Full Text] [Related]
19. In Vivo Biokinetics of
Beykan S; Fani M; Jensen SB; Nicolas G; Wild D; Kaufmann J; Lassmann M
Contrast Media Mol Imaging; 2019; 2019():6438196. PubMed ID: 30733648
[TBL] [Abstract][Full Text] [Related]
20. Kidney dosimetry in 777 patients during
Sandström M; Freedman N; Fröss-Baron K; Kahn T; Sundin A
EJNMMI Phys; 2020 Dec; 7(1):73. PubMed ID: 33296054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
